Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

BACKGROUND: Olaparib (AZD2281), a PARP-1/2 inhibitor, has been extensively investigated in clinical trials. However, limited clinical data are available about its long-term safety and anti-tumour activity. METHODS: Patients had first participated in a phase I study of olaparib combined with carbopla...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Noll, Ruud, Marchetti, Serena, Steeghs, Neeltje, Beijnen, Jos H, Mergui-Roelvink, Marja W J, Harms, Emmy, Rehorst, Harriet, Sonke, Gabe S, Schellens, Jan H M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522644/
https://www.ncbi.nlm.nih.gov/pubmed/26180927
http://dx.doi.org/10.1038/bjc.2015.256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522644/
https://www.ncbi.nlm.nih.gov/pubmed/26180927
http://dx.doi.org/10.1038/bjc.2015.256

Ejemplares similares